OM:CAMXPharmaceuticals
Camurus (OM:CAMX) Valuation After FDA Review Acceptance For Oclaiz NDA
Why the FDA review of Oclaiz matters for Camurus
The fresh interest in Camurus (OM:CAMX) centers on the FDA’s decision to accept for review the resubmitted New Drug Application for Oclaiz, its extended release octreotide injection for acromegaly.
This follows marketing authorization and an early launch in the EU and UK under the name Oczyesa, and it gives investors a clearer timetable, with a PDUFA target action date set for 10 June 2026.
See our latest analysis for Camurus.
The FDA review...